News
EU panel rejects Pfizer's tanezumab for osteoarthritis pain
Any lingering hope that Pfizer may finally get a regulatory approval for its nerve growth factor (NGF) inhibitor tanezumab looks to have been dashed after the EMA's human medicines committe
